Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Busulfan exposure dose tested for MDS and AML

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 1999

Dr Ravi Vij - Washington University School of Medicine, St Louis, USA

Dr Rav Vij, Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, talks to ecancertv at ASH 2014 about the CALGB 100801 study.

This is a phase II multi-centre NCI cooperative group study of the addition of azacitidine to reduced-intensity conditioning (RIC) allogeneic transplantation for higher risk myelodysplasia and older patients with acute myeloid leukaemia (AML).

The preliminary results suggest a strategy of targeting busulfan exposure to an AUC (area under the curve) of 4000uM*min based on a prior 'test dose' is successful in the majority of patients without causing excessive non-haematologic toxicity even in older patients.

Further follow up is necessary to determine whether this results in less relapse and improved progression free survival.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation